Clik here to view.
WHO members miss deadline for pandemic accord draft, will continue talks
Member countries of the World Health Organization said they failed to agree on a draft of a long-awaited pandemic agreement by a deadline last week, but the group will continue talks ahead of a major...
View ArticleAbbVie goes deeper into neuroscience with collaboration worth as much as $2B
In its next big neuro deal, AbbVie is betting $65 million — and another $1.95 billion in potential payments — on a platform that aims to achieve the efficacy of psychedelic compounds with fewer side...
View ArticlePfizer submits trademark application that suggests it could be launching a...
Pfizer may be the next pharma giant to launch a direct-to-consumer platform. The company applied in April to trademark “Pfizer for All” for a number of uses, including online retail pharmacy services...
View ArticleAmazon veteran Missy Krasner shares why now is the time for young health...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) If you want to get a pulse on digital health, Missy Krasner is an excellent person to ask. For the last...
View ArticleClik here to view.
Exclusive: AstraZeneca, BMS and Takeda partner with Harvard startup using AI...
Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed drug discovery collaborations with AstraZeneca, Bristol Myers Squibb and...
View ArticleNovo Nordisk reports four-year weight loss data on Wegovy
In a new analysis of Novo Nordisk’s vast SELECT study, researchers may have a better answer for one of the biggest questions surrounding GLP-1s — how long can the weight loss last? Among trial...
View ArticleBayer cuts 1,500 staffers companywide in campaign to reduce bureaucracy
More details have started to emerge on how exactly Bayer is executing its broader company restructuring. The German conglomerate disclosed that 1,500 full-time employees had been laid off across...
View ArticleClik here to view.
The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer...
Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him in many directions, including running a research...
View ArticleAllogene's $110M offering; Apellis refinances
Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes: Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and...
View ArticleClik here to view.
Updated: Sands Capital raises $555M for third life sciences fund
Sands Capital said Tuesday it closed a $555 million life sciences fund, marking its third fund in the industry. The Arlington, VA-based long-term investor will devote the Pulse III fund to drug...
View ArticlePliant touts additional Phase 2a data for oral IPF drug that’s already in a...
Pliant Therapeutics unveiled more efficacy data from a small mid-stage trial of its lead candidate in idiopathic pulmonary fibrosis, which shows that its oral drug could potentially reverse fibrosis....
View ArticleWuXi AppTec trims 'small percentage' of workers at US site as market shifts
WuXi AppTec is cutting a small number of roles at a facility in St. Paul, MN, a company spokesperson told Endpoints News in an email. “This action was taken due to a shift in market conditions over the...
View ArticleClik here to view.
FDA offers more clarity on safety testing for cell therapies
The FDA is providing sponsors of cell therapies with a new draft guidance document on the kinds of safety testing they should perform. The 14-page guidance, published late last month, provides sponsors...
View ArticleDestruction of documents, insufficient data lead FDA to reject hep B vaccine...
Dynavax’s hepatitis B vaccine was rejected for a label expansion in the US after patient data was destroyed by a third-party clinical trial site operator, the company announced Tuesday. The complete...
View ArticleAscendis’ hypoparathyroidism drug saddled with three-month delay at FDA
Ascendis Pharma will likely wait three more months to get an answer from the FDA on the review of its hypoparathyroidism drug. On Tuesday, Ascendis announced that US regulators had delayed their...
View ArticleEisai heads to FDA with subcutaneous version of Alzheimer’s treatment...
Eisai and Biogen said Tuesday that they started an application for an under-the-skin maintenance dosing version of their Alzheimer’s treatment Leqembi. The subcutaneous submission was expected earlier...
View ArticleClik here to view.
BioMarin to lay off 170 staffers after pipeline reorg
Less than a month after revealing pipeline cuts amid disappointing gene therapy sales, BioMarin is now downsizing its team. The biotech said it will lay off about 170 workers worldwide after recent...
View ArticleClik here to view.
Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and...
Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California biotech said Tuesday afternoon that it is dropping its lead oncology asset, as...
View ArticleEisai projects near-term Leqembi sales 'considerably higher' than analyst...
Eisai is hoping to grow Leqembi sales 13-fold to around $360 million in fiscal year 2024, as it plans “aggressive investment” and looks to expand its Biogen-partnered Alzheimer’s drug’s market both in...
View ArticleClik here to view.
Updated: Blackstone commits $300M to a former Merck antibody for asthma, COPD
Blackstone’s next major bet is on a former Merck monoclonal antibody for atopic dermatitis that a new biotech will test for asthma and COPD. The alternative asset manager’s life sciences division,...
View Article